Cardiogenic Shock Clinical Trial
Official title:
Ultrasound Study of the Diaphragm Evolution Under ECMO
Evaluate the evolution of diaphragmatic muscle effort in cardiogenic shock in ECMO patient with ultrasounds during the first weaning attempt in intensive care patients.
Diaphragmatic atrophy and diaphragmatic dysfunction are described in human resuscitation
under mechanical ventilation, but this diaphragmatic function has not been studied in
patients with cardiogenic shock and also under cardiac assistance by extracorporeal
circulation called ECLS (Extra -corporeal Life support). Diaphragmatic dysfunction in
intensive care has been described during prolonged stay in intensive care and early sepsis.
It is associated with dyspnea and delayed weaning from mechanical ventilation. The atrophy of
the diaphragm muscle is related to both loss of function and also loss of muscle performance.
Decreases in heart muscle and diaphragm performance may require both cardiac and respiratory
assistance. Cardiac and respiratory dysfunctions can complicate the weaning of the
respiratory assistance and also extracorporeal circulatory support supports. These two
supports, respiratory and circulatory assistance, allow the purification of CO2 and
respiratory assistance is known to influence the diaphragmatic function. The role of the
muscular pump function in the withdrawal process of the ECLS, remains largely unknown. The
aim of our study is to give a description of the physiology of the diaphragm in case of
cardiogenic shock: we want to evaluate the force of the diaphragm according to the
ventilation under ECLS. No studies have yet evaluated the influence of ECLS as a CO2
purification system on the performance of the diaphragm muscle.
Ultrasound is used in the patient's bed in daily practice to measure cardiac function, vessel
study and diaphragm muscle. This method is reproducible and non-invasive. It can be
hypothesized that there is a muscular involvement of the diaphragm under extracorporeal
membrane oxygenation (ECMO) measurable by ultrasound method. Our main hypothesis is that the
diaphragm force evolves according to the cleaning of the CO2 by the ECLS during the weaning
of this one.
This is a Monocentric Prospective Observational Descriptive study. The objective of this
study is to evaluate prospectively and consecutively the evolution of diaphragmatic muscle
stress in cardiogenic shock with ultrasounds during the first ECMO weaning in intensive care
patients.
When cardiogenic shock occurs, during the first ECLS weaning, we also will evaluate
prospectively :
- The evolution of diaphragm muscle thickness
- The evolution of the function of the diaphragm muscle We will evaluate the impact of
different risk factors on the diaphragmatic function: respiratory variables, parameters
and duration of mechanical ventilation, ECLS parameters and duration, number and type of
associated organ failure, gasometric variables, hemodynamic variables, presence of a
cardiotomy.
And we also will evaluate the impact of the diaphragmatic function on the patient's future:
- Failure to wean from mechanical ventilation
- ECLS weaning failure
- Death in intensive care
- Length of stay in intensive care Patients will be informed and consents will be
collected during hospitalization in intensive care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |